Knowledge empowers. Action transforms.

Beth is a patient advocate, speaker, and author specializing in:

  • Venous thromboembolism VTE (deep vein thrombosis DVT and pulmonary embolism PE)
  • Anticoagulation
  • Adverse drug events
  • Pharmacy benefit management (PBM)
  • Insurance
  • Healthcare policy
  • Patient and family engagement
  • Patient empowerment

“a leading national patient advocate for action and progress on VTE”

Jack Jordan, Deputy Director CMS Partnership for Patients

Advocacy Bio

Beth Waldron, MA is an independent patient advocate from North Carolina.  In 2003, she experienced life-threatening deep vein thrombosis and pulmonary embolism which were initially misdiagnosed. As a result, she began working towards greater thrombosis education for patients and health care professionals, co-founding a medical education program at the University of North Carolina in Chapel Hill School of Medicine, Clot Connect.  After facing her own care access challenges, she became a national advocate for improving patient access to care. She has been published in numerous peer-reviewed medical journals including Research and Practice in Thrombosis and Haemostasis, the BMJ British Medical Journal, Circulation, the American Journal of Medicine as well as mainstream media.

Waldron has a nearly 30 year background volunteering and working in health care policy and program administration including for NC Medicaid, Blue Cross Blue Shield NC, The University of North Carolina at Chapel Hill Thrombosis Center and numerous health care nonprofits. She has previously served as a Member of the Clinical Practice Guideline Panel on Thrombophilia with the American Society of Hematology, a Member of the Centers for Disease Control and Prevention Division of Blood Expert Panel on Prevention Research, an Advisor on Patient and Family Engagement to the Centers for Medicare and Medicaid Partnership for Patients initiative targeting hospital-acquired conditions and a Member of the National Quality Forum Affinity Groups on venous thromboembolism and adverse drug events.